APOLLO+
Research type
Research Study
Full title
A prospective ‘real world data’ registry and sample collection study for patients with diffuse large B-cell lymphoma
IRAS ID
270224
Contact name
Nagesh Kalakonda
Contact email
Sponsor organisation
The Clatterbridge Cancer Centre NHS Foundation Trust
Duration of Study in the UK
2 years, 5 months, 31 days
Research summary
Research Summary
Diffuse large B-cell lymphoma (DLBCL) is a cancer of the lymphatic system. Approximately 5,500 people are diagnosed with DLBCL per year in the United Kingdom (UK), representing approximately 30-40% of people diagnosed with non-Hodgkin lymphoma (NHL). The usual treatment for patients newly diagnosed with DLBCL is a combination of anti-cancer drugs called R-CHOP which are given for approximately 6 months. In practice, around half the patients diagnosed with DLBCL are unsuitable for ‘full-dose’ R-CHOP due to other health conditions that increase the risk of side effects. Often, the dose has to be reduced or delayed and this is likely to reduce their effectiveness in treating the DLBCL.
A significant proportion (10-15%) of patients do not respond, or relapse shortly after their treatment. A further 20-25% relapse following an initial response to therapy. These patients have a poor prognosis and represent an area of unmet clinical need.
Although primary and secondary care data registries collect data on treatment and management of DLBCL, the quality and completeness is varied. A better understanding of patients who are A) ineligible for first-line treatment with full dose R-CHOP and B) patients with relapsed/refractory DLBCL is desirable.
This study will survey patients’ demographic and clinical characteristics, treatment pathways, and clinical outcomes in order to better characterise DLBCL and develop future studies. In addition, collection of and biobanking of relevant blood and biopsy samples linked to the data collection is designed to promote future research.
Eligible patients will be enrolled by NHS sites across the UK and will be followed for a maximum of 12 months post-treatment.
Summary Results
We had to give up on the Apollo plus study before we could start enrolling any patients. This happened because the setup of the trial got delayed due to various problems. When we looked at our budget, we realized it was going to cost more than we had planned. We applied for more funding but this request was unsuccessful. So, we had to make the difficult decision that we couldn't begin or continue the study. To Data was collected. We officially closed the study on January 23, 2023.
REC name
Wales REC 5
REC reference
21/WA/0025
Date of REC Opinion
14 Apr 2021
REC opinion
Further Information Favourable Opinion